对比增强作为恶性胶质瘤疾病负荷与治疗反应替代标志物的证据及使用情境
本文汇总神经肿瘤学领域数百项研究的证据,探讨CT或MRI脑内对比增强肿瘤大小作为恶性胶质瘤(包括胶质母细胞瘤)疾病负荷替代生物标志物及治疗反应测量工具的适用证据基础与具体使用情境。
要点
- 对比增强肿瘤大小作为诊断与疗效评估工具在恶性胶质瘤中仍存争议。
- 本文整合数百项研究证据,为对比增强肿瘤大小作为疾病负荷替代标志物提供证据基础。
- 文章明确了对比增强肿瘤大小用于测量恶性胶质瘤治疗反应的具体情境。
核心结论
- 文章整合大量证据,为将对比增强肿瘤大小视为恶性胶质瘤疾病负荷的适当替代生物标志物及治疗反应测量工具提供证据基础与具体使用情境。
研究设计与样本
- 本文为综述,汇总神经肿瘤学领域数百项研究的证据。
主要发现
- 数十年来,CT或MRI脑内对比增强一直被视为恶性胶质瘤诊断与治疗反应评估的金标准。
- 对比增强肿瘤大小的使用作为准确诊断和评估恶性胶质瘤治疗疗效的工具仍存争议,尤其在当前快速演变的治疗格局下。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of contrast enhancement within the brain on CT or MRI has been the gold standard for diagnosis and therapeutic response assessment in malignant gliomas for decades. The use of contrast enhancing tumor size, however, remains controversial as a tool for accurately diagnosing and assessing treatment efficacy in malignant gliomas, particularly in the current, quickly evolving therapeutic landscape. The current article consolidates overwhelming evidence from hundreds of studies in the field of neuro-oncology, providing the necessary evidence base and specific contexts of use for consideration of contrast enhancing tumor size as an appropriate surrogate biomarker for disease burden and as a tool for measuring treatment response in malignant glioma, including glioblastoma.
引用
- Ellingson BM, Wen PY, Cloughesy TF, et al. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol. 2018. PMID: 29040703. doi:10.1093/neuonc/nox193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。